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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not 
ramelteon is effective in improving sleep quality in adult patients with mild to moderate 
obstructive breathing disorders. 
 
Study Design: Review of three English studies published from 2007 to 2010; two 
randomized controlled studies and one randomized crossover study. 
 
Data sources: The double blind randomized placebo controlled crossover trial, 
randomized double blind placebo controlled two way crossover study and double blind 
placebo controlled randomized controlled trial were found using PubMed. 
 
Outcomes measured: Each of the studies measured the sleep quality in patients with 
either obstructive sleep apnea or COPD, which are both forms of chronic obstructive 
breathing disorders.  Sleep quality was measured using a post sleep questionnaire on a 
seven-point Likert scale or by using the Pittsburgh Sleep Quality Index. 
 
Results: Results from all three studies did not demonstrate any significant improvement 
in sleep quality in adult patients with mild to moderate obstructive breathing disorders. 
 
Conclusions:  Ramelteon has not been shown to improve sleep quality in adult patients 
with mild to moderate obstructive breathing disorders in the three studies reviewed.  
 
Key Words: Ramelteon, Obstructive Breathing disorders, Sleep Apnea, COPD, sleep 
quality 
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INTRODUCTION 
Patients with obstructive breathing disorders such as obstructive sleep apnea (OSA) and 
COPD can present many different ways.  Patients can present with irregular and abnormal 
respiratory patterns during sleep, loud snoring, snorts during their sleep, as well as restlessness 
and disrupted sleep.1 This paper evaluates a double blind randomized placebo controlled 
crossover trial, a randomized double blind placebo controlled two way crossover study and a 
double blind placebo controlled randomized controlled trial; comparing the efficacy of ramelteon 
in improving sleep quality in adult patients with mild to moderate obstructive breathing 
disorders. 
This topic is relevant to the PA profession and patients because it is a common issue 
among Americans, ramelteon is cost effective, and a high number of patients seek healthcare for 
obstructive breathing disorders.  It is estimated that there are 24 million Americans that have 
known airflow limitations.2 Currently 20% of North Americans have OSA, which is defined as 
having an apnea hypopnea index (AHI) greater than five events per hour, and 2-9% have an AHI 
greater than five events per hour with at least one symptom that responds to treatment.3 There is 
not an exact estimate on how much is spent on all obstructive breathing disorders annually, but it 
is estimated around $32 billion are spent on patients with COPD,4 and the costs for diagnosing 
and treating patients with OSA ranges between $2 billion and $10 billion dollars.5 There is not an 
exact estimate for how many patients with obstructive breathing disorders visited a healthcare 
facility for decreased sleep, however COPD accounts for 1.5 million emergency room visits, and 
726,000 hospitalizations annually.4 
There are many factors that can increase a patients chances of developing OSA, such as 
the size of the patients neck and the shape of their airway, swelling of a patients tonsils, smoking, 
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high blood pressure, risk factors of heart failure or stroke, and obesity.6 Continuous positive 
airway pressure (CPAP) is the main treatment used in patients with obstructive breathing 
disorders during sleep, but for patients who cannot tolerate or are not successful using the CPAP, 
the other options are limited to oral appliances or possible surgery.7 
 There are different treatments and therapies that are currently used to help improve sleep 
quality in patients with obstructive breathing disorders.  The main therapy used in patients with 
obstructive breathing disorders is a CPAP device, which helps to keep airflow greater during 
sleep.7 Patients also can use oxygen concentrators to increase the amount of oxygen received 
during sleep.  There are other oral appliances that can be used to help improve the sleep quality 
in patients with obstructive breathing disorders, such as mandibular repositioning appliances and 
tongue-retaining devices.7 Patients can also have surgery preformed to increase airflow during 
sleep.  These surgeries include uvulopalatopharyngoplasty, somnoplasty and nasal surgery.7 
Patients can also try to lose or manage their weight either medically with diet and exercise or 
with weight loss surgery.  Patients can use oral medications such as Ipatropium, Prednisone, 
Albuterol, Metaproterenol, and Roflumilast to decrease the symptoms of their obstructive 
breathing disorder and help improve their sleep quality.7 
Currently there is no cure for obstructive breathing disorders and decreased sleep, but the 
treatments listed above can help relieve the symptoms patient’s experience and sleep quality.  
Ramelteon can be used on patients to help allow the patient to fall asleep more quickly in 
patients who have sleep-onset insomnia.8 
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OBJECTIVE 
The objective of this selective EBM review is to determine whether or not ramelteon is 
effective in improving sleep quality in adult patients with mild to moderate obstructive breathing 
disorders. 
METHODS 
There are specific criteria that were used in the selection of participants for this study.  The 
population for this study was patients over 19 years of age with mild to moderate obstructive 
breathing disorders.  The intervention used was ramelteon.  During this study the effectiveness of 
ramelteon was compared to a visually similar placebo.  The outcome being measured for this 
study was the sleep quality in patients with mild to moderate obstructive breathing disorders 
based on the information obtained through the PQSI and Post sleep questionnaire.  The studies 
used were a two double blind randomized placebo controlled crossover trials, and a double blind 
placebo controlled, randomized controlled trial comparing the effectiveness of ramelteon to a 
visually similar placebo and its effect on sleep quality. 
The author used the keywords “ramelteon,” “obstructive breathing disorders,” and “sleep 
quality”, to search the PubMed database.  All studies that were included were found on the 
PubMed database and were published in English.  The articles were published in peer-reviewed 
journals.  The articles were selected based on the relevance to the clinical question and if the 
study outcomes would make a difference to the patient which would make the study a POEM.  
Inclusion criteria used were studies that were randomized controlled or crossover trials published 
after 1996.  Exclusion criteria included patients that had previously had surgery for obstructive 
breathing disorders, history of drug or alcohol abuse, currently using other sleep aids or 
fluvoxamine. 
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Statistics that were reported and used were p-values and confidence intervals. 
Table 1- Demographics and Characteristics of Included Studies 
 
Study Type #  
Pts 
Age 
 
Inclusion Criteria Exclusion Criteria W/D Intervention 
Kryger9 
(2007) 
RCT
- 
cross
over 
26 19-
64 
yrs 
Men, nonpregnant 
or nonlactating 
women w/ 
diagnosis of mild 
to moderate 
obstructive sleep 
apnea (AHI ≥ 5 
and ≤ 20 per hour 
of sleep) bedtime 
between 8:30 pm 
& 12:00 am w/ 4+ 
hours of sleep per 
night 
Surgery for sleep apnea, use 
PAP device w/in 30 days, 
hypersensitivity to 
ramelteon, study recently 
using ramelteon, 
uncontrolled systemic 
illness, hepatitis, sleep or 
CNS medications that alter 
sleep, recent sleep schedule 
changes, history of 
psychiatric disorder/drug 
abuse, seizure, periodic limb 
movement or sleep disorders 
0 Single dose 
of either 16 
mg of 
ramelteon or 
placebo 
separated by 
a 5- or 12-
day wash 
out period.  
Medication 
given 30 
minutes 
before 
bedtime 
 
Kryger10 
(2008) 
RCT
- 
cross
over 
26 51-
76 
yrs 
Clinical history of 
COPD, mild to 
moderate airflow 
limitation, post 
bronchodilator 
FEV1 change 
from baseline less 
than 12%, SaO2 
over 85% during 
sleep for 99% 
recording period, 
no SaO2 less than 
80%, SaO2 greater 
than 91% while 
awake, bedtime 
between 8:30 pm 
and 12:00 am. 
Periodic leg movement 
arousal index >20, acute 
illness w/in 2 wks, 
disease/psychiatric disorder, 
history of drug/alcohol abuse 
w/in one year, shift work 
w/in 3 months, flown across 
3+ time zones w/in 1 week, 
medication to affect sleep-
wake function w/in 1 wk, 
RVH, right heart failure, 
acute or chronic respiratory 
failure, severe COPD, 
oxygen, hypercapnia, apnea 
hypopnea index >15, 
hematocrit >55%, weight 
loss program w/in 30 days  
0 Single dose 
of either 16 
mg of 
ramelteon or 
placebo 
separated by 
a 5- or 12-
day wash 
out period.  
Medication 
given 30 
minutes 
before 
bedtime 
 
Goone-
ratne11 
(2010) 
RCT 21 >60 
yrs 
Patients over 60 
years old with a 
diagnosis of sleep 
apnea syndrome 
with a minimum 
of AHI of 5 
events/hour. 
Restless leg syndrome, 
periodic limb movement 
disorder, severe emphysema, 
alcohol abuse, cognitive or 
liver abnormalities, prior use 
of CPAP, actively use 
fluvoxamine/sedative 
hypnotics 
6 8 mg of 
Ramelteon 
or placebo 
given 30 
minutes 
before their 
bedtime for 
30 days 
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OUTCOMES MEASURED 
The outcomes in the studies from Kryger were used to assess sleep quality in subjects 
with COPD or the diagnosis of mild to moderate obstructive sleep apnea.9,10  These studies used a 
post-sleep questionnaire, which was measured using a seven-point Likert scale.9,10  The outcomes 
that were addressed in the Gooneratne et al study were the sleep quality in patients with 
obstructive sleep apnea.11  This was measured by using the Pittsburgh Sleep Quality Index 
(PSQI), which assesses sleep quality and its changes in insomnia.11  A higher PSQI indicated a 
worse sleep quality the subjects had encountered. The PSQI is rated on a 21 point score from a 
minimum score of 0 to a maximum score of 21.12 This study also originally asked the subjects to 
complete an at-home sleep diary, however less than half of the participants completed the sleep 
diary so it was excluded from the results.11   
RESULTS 
All three articles compared the use of ramelteon with a placebo for improving sleep 
quality in adult patients with mild to moderate obstructive breathing disorders.  Kryger et al9 is a 
double blind randomized placebo controlled crossover trial. Kryger et al10 is a randomized double 
blind placebo controlled two way crossover study.  Gooneratne et al11 is a double blind, placebo 
controlled, randomized controlled trial. Each article was presented as continuous data.9,10,11 
Kryger et al conducted a trial that involved 26 adults aged 51-76 with clinical history of 
COPD or mild to moderate airflow limitation.10 This study excluded patients with periodic leg 
movement arousal index >20, acute illness within 2 weeks, disease or psychiatric disorder, 
history of drug or alcohol abuse within one year, shift work within 3 months, patients that have 
flown across three or more time zones within one week, or it the patients have taken medication 
to affect their sleep-wake function within one week.10  Patients were also excluded if they had 
right ventricular hypertrophy, right heart failure, acute or chronic respiratory failure, severe 
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COPD, need for nocturnal oxygen, hypercapnia, apnea hypopnea index >15, hematocrit >55% or 
if they have participated in a weight loss program within 30 days.10  The patients were given a 
single dose of either 16 mg of ramelteon or a placebo, separated by a 5 or 12-day wash out 
period and then the patients received the other.  The medication was given 30 minutes before the 
participant’s bedtime. The participants used a seven-point scale post-sleep questionnaire to 
measure their sleep quality throughout the trial.10 The ramelteon mean difference from baseline 
was 3.5 and the mean difference for the placebo from baseline was 3.6.10 The mean difference 
between the ramelteon and placebo was 0.10 (Table 2).10 There was no statistical significance 
found with sleep quality in the subjects with the reported p-value (p=0.690) and a 95% CI of (-
0.5 , 0.4) (Table 3).10 
Kryger et al was a double blind, placebo controlled, randomized crossover trial.9 This 
trial excluded patients who have received surgery for sleep apnea, patients that have used 
positive airway pressure devices within 30 days, had a hypersensitivity to ramelteon in any 
previous study using ramelteon.9 It also excluded patients with uncontrolled systemic illness, 
hepatitis, other sleep or CNS medications that can alter sleep, with any recent sleep schedule 
changes, history of psychiatric disorders or drug abuse, patients with history of seizures, periodic 
limb movement disorders or other sleep disorders.9  In this trial 26 adults between 19 and 64 
years of age were given a single dose of either 16 mg of ramelteon or a placebo 30 minutes 
before their bedtime at a sleep center, followed by a 5 or 12-day washout period and then the 
patients were given the other.9 The medication was given 30 minutes before the participant’s 
bedtime. The participants sleep quality was assessed with a post-sleep questionnaire that used a 
seven-point Likert scale, ranging from “excellent” to “extremely poor.”9 The ramelteon mean 
difference from baseline was 3.8 and the mean difference for the placebo from baseline was 3.7.9 
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The mean difference between the ramelteon and placebo was 0.10 (Table 2).9 There was no 
statistical significance found with sleep quality in the subjects with the reported p-value 
(p=0.668) and a 95% CI of (-0.5 , 0.7) (Table 3).9 
Gooneratne et al was a double blind, placebo controlled, randomized control trial.11 This 
trial excluded patients with restless leg syndrome, periodic limb movement disorder, severe 
emphysema, alcohol abuse, cognitive or liver abnormalities, prior use of CPAP, and patients 
actively using fluvoxamine or sedative hypnotics.11 In this trial the participants were given 8 mg 
of Ramelteon or a placebo 30 minutes before their bedtime.  This study used intention to treat 
comparisons to decrease the chance of there being bias in excluding subjects from the analyzed 
groups.11 During the study six participants (22.2%) were lost and no worst-case analysis was 
performed.11 Of the 27 original participants chosen, 8 of the subjects using ramelteon and 13 of 
the subjects using the placebo were analyzed. 11 The participants sleep quality was measured with 
the Pittsburgh Sleep Quality Index.11 The subjects were given a pre and post intervention PSQI.11  
The subjects that received ramelteon had a mean difference from baseline of 10.45 and the 
subjects that received the placebo had a mean difference from baseline of 9.35 (Table 2).11  There 
was a mean difference of 1.11 points between the ramelteon and placebo groups (Table 2).11  
There was no statistical significance found with sleep quality in the subjects with the reported p-
value (p=0.5) and a 95% CI of (-1.20, 0.57) (Table 3).11 
Table 2- Efficacy of ramelteon when compared to placebo 
Study Group Mean (SD) difference 
Kryger9 Ramelteon   3.8 (0.25) 
Placebo   3.7 (0.25) 
Kryger 10 Ramelteon   3.5 (0.2) 
Placebo   3.6 (0.2) 
Gooneratne11 Ramelteon 10.45 
Placebo   9.35 
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Table 3- Efficacy of ramelteon in improving sleep quality in mild to moderate obstructive 
breathing disorders 
Study 95% CI p-value 
Kryger9 (-0.5 , 0.7) 0.668 
Kryger 10 (-0.5 , 0.4) 0.690 
Gooneratne11 (-1.20 , 0.57) 0.5 
  
Some adverse effects were noted by the Gooneratne et al study.  A total of four adverse 
effects occurred with ramelteon including gastrointestinal-diarrhea, dermatologic- skin ulcer, 
pulmonology- paranasal reaction, musculoskeletal fracture after being hit by a bicyclist.11 A total 
of two adverse effects occurred with the placebo including abdominal pain and gastrointestinal-
nausea.11 All these adverse effects were thought to be unrelated to the drug during the treatment 
and it was noted that none of the adverse events were severe.11 The adverse effects noted during 
Kryger et al with ramelteon were two headaches and one urinary tract infection.9  The two 
headaches were noted as possibly related but resolved with acetaminophen and the urinary tract 
infection was noted as unrelated and resolved spontaneously.9 
DISCUSSION  
Ramelteon works on MT1/MT2 receptors, and these receptors are involved in the 
circadian rhythm, which effects the sleep-wake cycle.9 Ramelteon is a melatonin receptor agonist 
and has been shown to have little effect on sleep apnea severity.11 Ramelteon is available to 
patients with a prescription, which could prevent some patients from trying this medication since 
other similar medications such as melatonin are available over the counter.13 The cost of 
ramelteon, brand name Rozerem, is around $250.00 per month without insurance.  Due to the 
higher cost, some patients may not be able to financially afford rameleteon.13 Several 
contraindications and concerns are taken into consideration when a patient is using ramelteon.13 
Patients with a history of angioedema when previously using ramelteon should not re-challenge, 
                                                            Fife, Ramelteon and Obstructive Breathing Disorders 	  	   9	  
and it is also contraindicated with the use of fluvoxamine.13 It is also important to take ramelteon 
immediately prior to the patient’s bedtime due to the rapid onset and cause of patients to become 
drowsy.13   
All three studies analyzed showed no significant improvement in sleep quality in adult 
patients with mild to moderate obstructive breathing disorders when comparing ramelteon to the 
use of a placebo.  The small sample sizes in all three studies, between 21 and 26 subjects, may 
not accurately represent the total population of patients with obstructive breathing disorders.  In 
Gooneratne et al there was a 50% adherence to the APAP which could cause the patients to have 
a poorer sleep quality due to reasons other than the study drug.11 Having subjects with an age 
range of 19 and older allows for less precision, as sleeping habit and sleep quality change over 
time.  The younger subjects and older subjects may have very different baselines making it 
difficult to compare the two in one study.  Although the studies using a crossover design did 
have a wash out period between interventions, a carry-over effect may still have been present in 
some patients. 
CONCLUSION 
 Based on this systematic review and the studies analyzed, ramelteon is not effective in 
improving sleep quality in adult patients with mild to moderate obstructive breathing disorders.  
These three studies show no statistically significant data to support the improvement of sleep 
quality.  No severe adverse effects were noted in any of the three studies. Although the studies 
analyzed did not show that ramelteon improved sleep quality, future studies could be performed 
with larger populations to more accurately represent the population with obstructive breathing 
disorders. In the studies analyzed above, both Kryger et al studies monitored the subjects 
overnight, while Gooneratne et al sent the participants home with either the ramelteon or 
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placebo. 9,10,11 In future studies, patients should all receive their medications at a sleep center, 
which would allow them to be monitored taking the medication, using the APAP machine and 
improve the completion of post-sleep questionnaires.  
 
	  
References 
1. Obstructive sleep apnea. WebMD Web site. http://www.webmd.com/sleep-
disorders/guide 
/understanding-obstructive-sleep-apnea-syndrome. Published October 6, 2012. Updated 
2012. Accessed September 28, 2013 
2. Punturieri A, Croxton T, Weinmann G, Kiley J. Chronic obstructive pulmonary 
disease. National Institutes of Health Web site. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720113/. Published 2008. Updated 
2008. Accessed September/28, 2013. 
3. Strohl K. Overview of obstructive sleep apnea in adults. Up To Date Web site. 
http://ezproxy. 
pcom.edu:2076/contents/overview-of-obstructive-sleep-apnea-in-
adults?detectedLanguage 
=en&source=search_result&search=obstructive+sleep+apnea&selectedTitle=1%7E150&
provider=noProvider. Published February 12, 2013. Updated 2013. Accessed September 
28, 2013. 
4. Dalal A, Shah M, D'Souza A, Mapel D. COPD- Related Healthcare utilization and 
costs after disharge from a hospitalization or emergency department.  The American 
Journal of Managed Care Web site. http://www.ajmc.com/publications/issue/2011/2011-
3-vol17-n3/AJMC_11mar 
DalalWebX_e55toe65. Published 2011. Updated 2011. Accessed September/28, 2013.  
5. Cai Q, Tan H, Singer J. Impact of Positive Airway Pressure among Obstructive Sleep 
Apnea Patients.  The American Journal of Managed Care Web site.  
http://www.ajmc.com/publications/ 
issue/2012/2012-6-vol18-n6/Impact-of-Positive-Airway-Pressure-Among-Obstructive-
Sleep-Apnea-Patients.  Published 2012.  Updated 2012. Accessed September/28, 2013 
6. Hadjiliadis D. Obstructive sleep apnea. Medline Plus Web site. 
http://www.nlm.nih.gov/med 
lineplus/ency/article/000811.htm. Published 2011. Updated 2011. Accessed September 
28, 2013.  
7. Chronic obstructive pulmonary disease fact sheet. American Lung Association Web 
site. http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-
Sheet.html. Published 2013. Updated 2013. Accessed September 28, 2013.  
8. Ramelteon. Medline Plus Web site. 
http://www.nlm.nih.gov/medlineplus/druginfo/meds/ 
a605038.html. Published 2009. Updated 2009. Accessed September 28, 2013.  
	  
9. Kryger M, Wang-Weigand S, Roth T. Safety of Ramelteon in Individuals with Mild to 
Moderate Obstructive Sleep Apnea. Sleep Breath. 2007;11(3):159-164. doi: 
10.1007/s11325-006-0096-4.  
10. Kryger M, Wang-Weigand S, Zhang J, Roth T. Effect of ramelteon, a selective 
MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. 
Sleep Breath. 2008;12(3):243-250. doi: 10.1007/s11325-007-0156-4.  
11. Gooneratne NS, Gehrman P, Gurubhagavatula I, Al-Shehabi E, Marie E, Schwab R. 
Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep 
apnea: A randomized placebo-controlled pilot study. J Clin Sleep Med. 2010;6(6):572-
580.  
12. Buysse,D.J., Reynolds,C.F., Monk,T.H., Berman,S.R., & Kupfer,D.J. The Pittsburgh 
Sleep Quality Index (PSQI): A new instrument for psychiatric research and practice. 
Psychiatry Research, (2008) 28(2), 193-213. 
13.  Ramelteon: Drug Information. UpToDate website. 
http://www.uptodate.com/contents/ramelteon-drug-
information?source=search_result&search= ramelteon&selectedTitle=1%7E14. Updated 
2013. Accessed November 30, 2013. 	  
